A new recommendation from the U.S. Preventive Services Task Force (USPSTF) advises against prostate cancer screening for men...
Primary-care practitioner beliefs about prostate-cancer screening account for much of the variability in the use of an informed-decision-making process.
Level 2: Mid-level evidenceIn two recent randomized trials, prostate cancer screening did not appear to show clinically significant benefits. The large European Randomized Study of Screening for Prostate Cancer (ERSPC) evaluated prostate-specific antigen (PSA) testing in 182,000 men with median follow-up of nine years (N Engl J Med. 2009;360:1320-1328; available at content.nejm.org/cgi/content/full/360/13/1320, accessed May 12,…
Odds of choosing screening up for men with family history, African descent, low socioeconomic status.
The USPSTF has updated its 2012 recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer.
In the United States, the rate of prostate cancer screening is down, and the number of men diagnosed with the disease has also dropped.
Replacing carbohydrates and animal fat with vegetable fat may reduce prostate cancer mortality.
Prostate cancer is the most common male-related malignancy in the US, the second most common cause of cancer-related death among men.
Prostatitis I. What every physician needs to know. Prostatitis refers to lower urinary tract symptoms caused by infection, inflammation, or irritation of the prostate gland. Prostatitis is a common presentation and occurs in men less than 50 years old. Most prostate disorders are managed in the ambulatory care setting. As few as 1% of cases…
Based on the evidence, the U.S. Preventive Services Task Force gave a grade D recommendation against PSA-based screening for men in the general U.S. population, regardless of age.